Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ophthalmologists

Articles with lock require a subscription to GLG News | Request a free trial
October 30, 2007
Mixing/Matching Multifocal and Accommodating IOLs
Analysis of: Visual performance of patients with bilateral vs combination Crystalens, ReZoom, and ReSTOR intraocular lens implants | www.ncbi.nlm.nih.gov
Author: GLG Expert Contributor
IOL technology has improved dramatically over the past decade.  However, the current multifocal/accommodating lenses (i.e., ReSTOR, ReZoom, and Crystalens) each have their own strengths and weaknesses.  The topic of matching or mixing lenses has therefore become very important.
October 29, 2007
American Academy of Ophthalmology Issues Press Statement Criticizing Genentech's Decision to Limit Avastin Availability for the Treatment of Wet Macular Degeneration
Analysis of: Ophthalmologists Concerned About AMD Patients’ Access To Avastin | aao.org
Author: GLG Expert Contributor
The American Academy of Ophthalmology said the recent decision by Genentech to limit availability of Avastin (bevacizumab) to compounding pharmacies could have a significant negative impact on the care of patients with age-related macular degeneration [AMD]. Dr. Charles Wilkinson, president of the AAO,...
Mark PackerOctober 22, 2007
Mixing and Matching of IOLs Shows Strengths, Weaknesses
Analysis of: Visual performance of patients with bilateral vs combination Crystalens, ReZoom, and ReSTOR intraocular lens implants | www.ncbi.nlm.nih.gov
Author: Mark Packer, Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Presbyopia correcting IOLs currently represent 5% of all IOLs implanted in the United States (about 3.5 million per year).  The products available in this category include the ReSTOR multifocal IOL (Alcon), the ReZoom multifocal IOL (AMO) and the cyrstalens accommodative IOL (eyeonics).  Although...
October 22, 2007
BREAKING NEWS: GENETECH TO RESTRICT THE AVAILABILITY OF AVASTIN IN ORDER TO LIMIT ITS USE OVER ITS MORE EXPENSIVE FDA APPROVED MEDICINE (LUCENTIS) FOR WET MACULAR DEGENERATION
Analysis of: Genentech to cease supplying bevacizumab to compounding pharmacies | www.osnsupersite.com
Author: GLG Expert Contributor
Genentech, Inc.  is suspending sales of Avastin (bevacizumab) to compounding pharmacies in the United STates, in an effort to curb its non approved use for wet macular degenration. Recently, ophthalmologists have begun using the antiangiogenic cancer drug off-label to treat retinal neovascularization...
October 16, 2007
Interesting Approach to the Lucrative Dry Eye Market
Analysis of: Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 | www.pipelinereview.com
Author: GLG Expert Contributor
Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small...
October 16, 2007
Genentech (DNA) may win the Battle but could Lose the War in Macular Degeneration.
Analysis of: Genentech to Limit Avastin Availability | online.wsj.com
Author: GLG Expert Contributor
Genentech is aiming to curb the off-label use of Avastin in favor of its blockbluster AMD drug Lucentis (which costs 50x more!).  These attempts will make it more difficult to prescribe Avastin and help them boost sales of Lucentis in the short term.  However, in the long term, Genentech is...
October 16, 2007
Another new player (ALTY-0501) in the limited Dye Eye Market?
Analysis of: Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 | www.pipelinereview.com
Author: GLG Expert Contributor
ALTY-0501 is new medication being used in the Dry Eye Market.  This reports reveals positive results from a Phase 2 Study.  It is exciting as there are limited products for treating Dry Eye; and this could be a new rival from Restatisis (Allergan; AGN).
October 16, 2007
Antioxidant Supplements Do NOT prevent Early Macular Degeneration.
Analysis of: Antioxidants Don't Prevent Macular Degeneration | www.medpagetoday.com
Author: GLG Expert Contributor
An extensive meta-analysis by Wong et al involving a 149,203 patients shows that antioxidants do not prevent early macular degeneration (the formation of drusen.)  However, it does not refute the role of antioxidants in preventing wet or advanced macular degeneration (AMD). ...
October 16, 2007
Genentech (DNA) is losing Credibilty among Retina Specialists for Macular Degeneration.
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye | www.nytimes.com
Author: GLG Expert Contributor
Genetech (DNA) is looking to curb the off label use of its oncology medications (Avastin) in order to boost Lucentis sales.  It is a terrible PR move for the company that exposes its greed and bumbling moves but a good fianancial decision to maximize its profits for Lucentis. 
October 15, 2007
Restriction on Avastin distribution will add to Genenetech's bottom line.
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye | www.nytimes.com
Author: GLG Expert Contributor
       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 158

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617